Marlene Dressman

Marlene Dressman is an accomplished professional in the field of oncology and clinical development, currently serving as Executive Director and Global Project Leader at AstraZeneca since February 2016, overseeing both early and late-stage oncology projects, including notable drugs such as olaparib and durvalumab. Prior experience includes leadership roles at Vanda Pharmaceuticals from July 2003 to January 2016, and Novartis Pharmaceuticals from March 1999 to June 2003, where Marlene made significant contributions to gene expression analysis and clinical pharmacogenetics. Early career positions include research roles at the National Institutes of Health and the University of Pittsburgh, where Marlene focused on genetic research and the development of transgenic animal models. Marlene Dressman holds a Ph.D. in Human Genetics from the University of Pittsburgh and a B.A. in Microbiology from UC Santa Barbara.